CR20230614A - Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos - Google Patents

Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos

Info

Publication number
CR20230614A
CR20230614A CR20230614A CR20230614A CR20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A CR 20230614 A CR20230614 A CR 20230614A
Authority
CR
Costa Rica
Prior art keywords
oxoisoindolin
dione
piperidine
derivatives
medical uses
Prior art date
Application number
CR20230614A
Other languages
English (en)
Inventor
Simone Bonazzi
Janetta Dewhurst
Pamela Yf Ting
Gary O'brien
John Ryan Kerrigan
Mooje Sung
Jennifer Stroka Cobb
Artiom Cernijenko
Noel Marie-France Thomsen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20230614A publication Critical patent/CR20230614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a compuestos de fórmula (I), composiciones farmacéuticas que los comprenden, y su uso para reducir los niveles de expresión de los motivos de dedos de zinc ampliamente interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y en el tratamiento de trastornos sanguíneos hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, beta–hemoglobinopatías), tales como la enfermedad de células falciformes y beta–talasemia.
CR20230614A 2021-06-03 2022-06-01 Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos CR20230614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03
PCT/IB2022/055131 WO2022254362A1 (en) 2021-06-03 2022-06-01 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof

Publications (1)

Publication Number Publication Date
CR20230614A true CR20230614A (es) 2024-02-01

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230614A CR20230614A (es) 2021-06-03 2022-06-01 Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos

Country Status (22)

Country Link
US (2) US12103919B2 (es)
EP (1) EP4347580A1 (es)
JP (1) JP2024520654A (es)
KR (1) KR20240013812A (es)
CN (1) CN117062811A (es)
AR (1) AR126052A1 (es)
AU (1) AU2022284366A1 (es)
BR (1) BR112023024905A2 (es)
CA (1) CA3215410A1 (es)
CL (1) CL2023003561A1 (es)
CO (1) CO2024000013A2 (es)
CR (1) CR20230614A (es)
DO (1) DOP2023000261A (es)
EC (1) ECSP24000004A (es)
IL (1) IL308094A (es)
JO (1) JOP20230308A1 (es)
MX (1) MX2023014327A (es)
PE (1) PE20240657A1 (es)
PY (1) PY2243958A (es)
TW (1) TW202306570A (es)
UY (1) UY39796A (es)
WO (1) WO2022254362A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
US20250333407A1 (en) * 2024-04-29 2025-10-30 Bristol-Myers Squibb Company Compounds and Their Use for Treatment of Hemoglobinopathies
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
CN121605108A (zh) * 2024-06-25 2026-03-03 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP2015524811A (ja) 2012-07-27 2015-08-27 セルジーン コーポレイション イソインドリン−１，３−ジオン化合物の調製プロセス
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
IL290809B2 (en) 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
MX2019007646A (es) 2016-12-23 2019-09-06 Arvinas Operations Inc Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
WO2019079701A1 (en) 2017-10-20 2019-04-25 Dana-Farber Cancer Institute, Inc. HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
KR20250020690A (ko) 2018-06-29 2025-02-11 다나-파버 캔서 인스티튜트 인크. 세레블론(crbn)에 대한 리간드
US12060366B2 (en) 2018-06-29 2024-08-13 Dana-Farber Cancer Institute, Inc. Bispecific degraders
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
EP3813834B1 (en) 2018-06-29 2025-03-26 Dana-Farber Cancer Institute, Inc. New crbn modulators
DK3820573T3 (da) * 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
US12227488B2 (en) * 2018-12-03 2025-02-18 Dana-Farber Cancer Institute, Inc. Small molecule degraders of Helios and methods of use
JP2022548095A (ja) 2019-09-16 2022-11-16 ノバルティス アーゲー 接着分解剤及びその使用方法
CN115397821B (zh) * 2019-10-17 2024-09-03 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
JP7682181B2 (ja) * 2019-12-18 2025-05-23 ノバルティス アーゲー ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用

Also Published As

Publication number Publication date
JP2024520654A (ja) 2024-05-24
US12103919B2 (en) 2024-10-01
CN117062811A (zh) 2023-11-14
EP4347580A1 (en) 2024-04-10
PE20240657A1 (es) 2024-04-04
ECSP24000004A (es) 2024-02-29
MX2023014327A (es) 2023-12-13
KR20240013812A (ko) 2024-01-30
BR112023024905A2 (pt) 2024-02-20
WO2022254362A1 (en) 2022-12-08
DOP2023000261A (es) 2023-12-29
TW202306570A (zh) 2023-02-16
AR126052A1 (es) 2023-09-06
CA3215410A1 (en) 2022-12-08
AU2022284366A1 (en) 2023-10-26
CL2023003561A1 (es) 2024-06-28
CO2024000013A2 (es) 2024-01-25
US20230019617A1 (en) 2023-01-19
US20250026736A1 (en) 2025-01-23
PY2243958A (es) 2023-01-20
UY39796A (es) 2023-07-31
JOP20230308A1 (ar) 2023-11-29
IL308094A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CO2022008243A2 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
CR20230614A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos
CO2023013486A2 (es) Derivados de pirazolopiridina y sus usos
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
DOP2011000218A (es) Derivados de sulfonamida
BR112015018491A2 (pt) triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
ES2187300B1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
CR9722A (es) Derivados de benzilpiperazina y su uso medico
CY1115734T1 (el) Συνθεσεις benzenesulfonamide, μεθοδος συνθεσης τους, και χρηση αυτων στην ιατρικη
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
BR112014026776A2 (pt) derivados de pirimidina para o tratamento de doenças bacterianas
MX382521B (es) Nuevos compuestos bioaromaticos de propinilo, composiciones farmaceuticas y cosmeticas que contienen los mismos y usos de los mismos.
MX2011012595A (es) Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.
AR130804A1 (es) Compuestos para la activación de la ampk
UY29063A1 (es) Derivados del ácido acético con sustituyentes ciclohexilmetoxi, procedimiento para su preparación y su uso como medicamentos
PA8641601A1 (es) Derivados del acido acetico con sustituyentes ciclohexilmetoxi, procedimiento para su preparacion y su uso como medicamentos
DOP2005000153A (es) Derivados del acido con sustituyentes ciclohexilmetoxi, procedimiento para preparacion y su uso como medicamentos.
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas
DOP2003000663A (es) Derivados de indolinfenilsulfonamida